BMO Capital Starts Ambit Biosciences (AMBI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Leerink Swann Starts Ambit Biosciences (AMBI) at Outperform
June 10, 2013 7:51 AM EDTLeerink Swann initiated coverage on Ambit Biosciences (NASDAQ: AMBI) with an Outperform rating and a price target of $14.00.
Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3... More
Citi Starts Ambit Biosciences (AMBI) at Buy
June 10, 2013 7:08 AM EDTCiti initiates coverage on Ambit Biosciences (NASDAQ: AMBI) with a Buy. PT $13.00.
For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.
Shares of Ambit Biosciences closed at $7.79 yesterday, with a 52 week range of $6.22-$8.24.... More
